Table 3.
Accuracy and efficiency and quality assessment n (%)
| MRS1 (n = 312) | MRS2 (n = 276) | MRS3 (n = 431) | Overall (n = 1019) | |
| AC: (TP+TN)/N | 0.97 | 0.87 | 1 | 0.95 |
| ST: TP/N (D+) | 0.85 | 0.79 | 0.99 | 0.93 |
| SP: TP/N (D-) | 1 | 1 | 1 | 1 |
| PPV: TP/N (T+) | 1 | 1 | 1 | 1 |
| NPV: TN/N (T-) | 0.97 | 0.76 | 0.95 | 0.90 |
| +LR (ST/1-SP) | 0 | 0 | 0 | 0 |
| -LR (SP/1-ST) | 6.6 | 4.7 | 100 | 4.2 |
| TP | 36 (3.5) | 109 (10.6) | 370 (36) | 616 (60.4) |
| TN | 231 (22.6) | 101 (9.9) | 26 (2.5) | 403 (39.5) |
| IT | 39 (12.5) | 55 (19.9) | 35 (8.1) | 129 (12.6) |
| TDCD mean days (range) | 25.4 (8-32)c | 16.2 (11-24)a | 12.4 (10-21)a | 16.3 (8-32) |
| Patients TP treated with surgery or CRT | 36 (3.5)c | 109 (10.7)a | 370 (36.3)a | 515 (50.5) |
| Patients with inconclusive tests treated (surgery-CRT) | 16 (9-7) | 21 (12-9) | 18 (13-5) | 55 (34-21) |
Calculation of accuracy (AC), sensitivity (ST), specificity (SP), and positive (PPV) and negative (NPV) predictive values for malignant risk score (MRS)-1, MRS-2 and MRS-3, likelihood ratios for positive and negative test (+LR, -LR) for different groups of patients. D+: Number of patients with positive final diagnosis; D-: Number of patients with negative final diagnosis; IT: Inconclusive test; TDCD: Time to definitive cytological diagnosis; CRT: Chemo-Radio-Therapy.
a
P < 0.05 vs MRS1;
c
P < 0.05 vs MRS3 according to the Scheffé post-hoc test.